LIXTE Biotechnology Holdings (NASDAQ: LIXT) announced it has filed its Annual Report on Form 10-K for the year ended Dec. 31, 2025, outlining a year marked by leadership changes, clinical progress and strategic expansion. The company advanced development of its lead compound LB-100, expanded clinical trials with additional sites and increased enrollment, completed the acquisition of Liora Technologies Europe Ltd. to enhance its cancer treatment platform, and raised more than $11 million to strengthen its balance sheet, as it positions for continued growth and innovation in oncology.
The filing underscores key milestones for the clinical-stage pharmaceutical and med-tech company. LB-100, a first-in-class clinical PP2A inhibitor, has demonstrated tolerability in cancer patients at doses associated with anti-cancer activity. Based on published preclinical data, LB-100 has the potential to significantly enhance chemotherapies and immunotherapies and improve outcomes for patients with cancer. It is part of a pioneering effort in an entirely new field of cancer biology – activation lethality – that is advancing a new treatment paradigm. Proof-of-concept clinical trials are currently in progress for Ovarian Clear Cell Carcinoma, Metastatic Colon Cancer and Advanced Soft Tissue Sarcoma, as detailed in the company's press release.
The acquisition of Liora Technologies Europe Ltd. adds a complementary dimension to LIXTE's oncology focus. Through its wholly owned subsidiary, LIXTE is pioneering the development of electronically controlled proton therapy systems for treating tumors. Liora's proprietary flagship technology, the LiGHT System, is believed to provide significant advantages over currently available technologies for treating tumors with proton therapy. This strategic move positions the company at the forefront of both pharmaceutical and medical device innovation in cancer care.
Financially, the company raised more than $11 million during the year, bolstering its balance sheet to support ongoing research and development. The capital infusion, combined with the clinical progress and strategic acquisition, reflects a transformative period for LIXTE. The company's comprehensive patent portfolio covers its novel approach to cancer biology, providing a foundation for future growth.
Investors and stakeholders can access the full details of the annual report and forward-looking statements through the company's filings with the SEC. As noted in the press release, forward-looking statements involve risks and uncertainties, and the company undertakes no duty to update this information unless required by law. Additional information about LIXTE and its subsidiaries is available at www.lixte.com.
